Belpointe Asset Management’s AC Immune ACIU Stock Holding History

Belpointe Asset Management’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,000	Closed	-$2.34K	–	637
2023 Q1	$2.34K	Hold	1,000	–	–	﹤0.01%	3267
2022 Q4	$2.04K	Buy	+1,000	New	+$2.58K	﹤0.01%	3253
2018 Q4	–	Sell	-50,000	Closed	-$400K	–	495
2018 Q3	$400K	Buy	+50,000	New	+$503K	0.06%	304
2018 Q1	–	Sell	-50,750	Closed	-$650K	–	347
2017 Q4	$650K	Sell	50,750 -350	-0.7%	-$4.12K	0.14%	161
2017 Q3	$571K	Buy	+51,100	New	+$437K	0.13%	166

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Belpointe Asset Management's ACIU Position: Q2 2023 in Review

Belpointe Asset Management sold out of AC Immune (ACIU) in Q2 2023, closing a stake of 1,000 shares — an estimated $2.34K sold.

Belpointe Asset Management first reported a position in ACIU in Q3 2017 and held it in 5 quarters. The position peaked at $650K in Q4 2017. 31 funds tracked by Wall St. Rank hold ACIU as of Q2 2023.

Belpointe Asset Management reported no remaining AC Immune position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 1,000 AC Immune shares in Q2 2023, an estimated $2.34K.
Belpointe Asset Management first reported a position in AC Immune in Q3 2017 and held it in 5 quarters.
Belpointe Asset Management's AC Immune position peaked at $650K in Q4 2017.
31 funds tracked by Wall St. Rank held AC Immune as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.